Unravelling the proteome of formalin-fixed paraffin-embedded tissue

Briefings in Functional Genomics and Proteomics

Volumn 5, Issue 2, 2006, Pages 169-175

  Hood, Brian L ^a   Conrads, Thomas P ^a   Veenstra, Timothy D ^a  

^a SAIC FREDERICK INC   (United States)

Author keywords

Biomarker discovery; Formalin fixed paraffin embedded tissue; Laser capture microdissection; Mass spectrometry; Proteomics

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; BIOLOGICAL MARKER; FORMALDEHYDE; JANUS KINASE 1; PARAFFIN; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN KINASE C; RAF PROTEIN; STAT1 PROTEIN; FIXATIVE; PROTEOME; TUMOR PROTEIN;

BIOPSY TECHNIQUE; BODY FLUID; CLINICAL FEATURE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; EMBEDDING; FROZEN SECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LASER CAPTURE MICRODISSECTION; MASS SPECTROMETRY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN ISOLATION; PROTEOMICS; REVIEW; TANDEM MASS SPECTROMETRY; TISSUE FIXATION; ANIMAL; ARTICLE; CHEMISTRY; LASER; MALE; MICRODISSECTION; PROSTATE TUMOR;

ANIMALS; BIOLOGICAL MARKERS; FIXATIVES; FORMALDEHYDE; LASERS; MALE; MASS SPECTROMETRY; MICRODISSECTION; NEOPLASM PROTEINS; PARAFFIN EMBEDDING; PROSTATIC NEOPLASMS; PROTEOME; TISSUE FIXATION;

EID: 33748526842     PISSN: 14739550     EISSN: 14774062     Source Type: Journal    
DOI: 10.1093/bfgp/ell017     Document Type: Review

References (18)

1. Anderson NL, Polanski M, Pieper R, et al. The human plasma proteome: A nonredundant list developed by combination of four separate sources. Mol Cell Proteomics 2004;3:311-26.
2. States DJ, Omenn GS, Blackwell TW, et al. Challenges in deriving high-confidence protein identifications from data gathered by a HUPO plasma proteome collaborative study. Nat Biotechnol 2006;24:333-8.
3. Fox CH, Johnson FB, Whiting J, et al. Formaldehyde fixation. J Histochem Cytochem 1985;33:845-53.
4. Kunkel GR, Mehrabian M, Martinson HG. Contact-site cross-linking agents. Mol Cell Biochem 1981; 34:3-13.
5. Wilkinson EJ, Hendricks JB. Role of the pathologist in biomarker studies. J Cell Biochem Suppl 1995;23:10-8.
6. Werner M, Chott A, Fabiano A, et al. Effect of formalin tissue fixation and processing on immunohistochemistry. Am J Surg Pathol 2000;24:1016-9.
7. Kadkol SS, Gage WR, Pasternack GR. In situ hybridization-theory and practice. Mol Diagn 1999;4: 169-83.
8. Ahram M, Flaig MJ, Gillespie JW, et al. Evaluation of ethanol-fixed, paraffin-embedded tissues for proteomic applications. Proteomics 2003;3:413-21.
9. Hood BL, Darfler MM, Thomas G, et al. Proteomic analysis of formalin-fixed prostate cancer tissue. Mol Cell Proteomics 2005;4:1741-53.
10. Crockett DK, Lin Z, Vaughn CP, et al. Identification of proteins from formalin-fixed paraffin-embedded cells by LC-MS/MS. Lab Invest 2005;85:1405-15.
11. Palmer-Toy DE, Krastins B, Sarracino DA, et al. Efficient method for the proteomic analysis of fixed and embedded tissues. J Proteome Res 2005;4:2404-11.
12. Liu H, Lin D, Yates JR, et al. Multidimensional separations for protein/ peptide analysis in the post-genomic era. Biotechniques 2002;32:898-902.
13. Guerrera IC, Kleiner O. Application of mass spectrometry in proteomics. Biosci Rep 2005;25:71-93.
14. Blonder J, Rodriguez-Galan MC, Lucas DA, et al. Proteomic investigation of natural killer cell microsomes using gas-phase fractionation by mass spectrometry. Biochem Biophys Acta 2004;1698:87-95.
15. Ong SE, Mann M. Mass spectrometry-based proteomics turns quantitative. Nat Chem Biol 2005;1:252-62.
16. Schneider LV, Hall MP. Stable isotope methods for high-precision proteomics. Drug Discov Today 2005;10: 353-63.
17. Ishihama Y, Oda Y, Tabata T, et al. Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein. Mol Cell Proteomics 2005;4:1265-72.
18. Brown DA, Stephan C, Ward RL, et al. Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis. Clin Cancer Res 2006;12:89-96.